Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapyKevin A. Hay, Cameron J. Turtle|Blood|2017Cited by 1.1k
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyRebecca Gardner, Cameron J. Turtle|Blood|2016Cited by 743
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cellsGermán G. Gornalusse, David W. Russell, Sarah E. Funk et al.|Nature Biotechnology|2017Cited by 623
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapyJoshua A. Hill, Cameron J. Turtle|Blood|2017Cited by 564
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A. Hay, Cameron J. Turtle|Blood|2019Cited by 399